Patents by Inventor Momar Ndao

Momar Ndao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGENIC SCHISTOSOMA COMPOSITIONS
    Publication number: 20230364209
    Abstract: The present disclosure provides an immunogenic composition comprising an emulsion of an epitope or a nucleic acid molecule. The emulsion comprises an oil phase and a water phase. The emulsion is an oil-in-water emulsion and/or a nanoemulsion. The epitope is present on a peptide or a polypeptide derived from Schistosoma sp. and can optionally be glycosylated. The immunogenic composition (which can be provided as a pharmaceutical composition or as a vaccine) can be used to prevent, treat or alleviation the symptoms of a Schistosoma sp. infection.
    Type: Application
    Filed: October 8, 2021
    Publication date: November 16, 2023
    Inventors: Momar NDAO, Dilhan Jonathan PERERA
  • VACCINES AND METHODS OF VACCINATION AGAINST SCHISTOSOMA
    Publication number: 20200316185
    Abstract: A method of immunizing a human against infection by parasitic worms, comprising orally administering a live attenuated recombinant bacterium, expressing at least one antigen corresponding to a parasitic worm antigen; and a sterile injectable vaccine comprising the at least one antigen corresponding to a parasitic worm antigen. The method is effective against worms, including schistosomes.
    Type: Application
    Filed: March 6, 2020
    Publication date: October 8, 2020
    Applicant: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Brian J. Ward, Adam Hassan, Momar Ndao
  • DETECTION OF SUBJECT BIOMARKER DIAGNOSTIC ASSAY FOR DENGUE FEVER AND THE DIFFERENTIATION OF DENGUE HEMORRHAGIC FEVER
    Publication number: 20150233921
    Abstract: Vitronectin is found to be a biomarker of progression from dengue fever to dengue hemorrhagic fever according to the present invention. Assay of vitronectin in biological samples of dengue virus infected subjects aids in prognosis, diagnosis and treatment of the disease, particularly in prediction of progression from dengue fever to severe dengue i.e. dengue hemorrhagic fever/dengue shock syndrome.
    Type: Application
    Filed: February 16, 2012
    Publication date: August 20, 2015
    Applicant: The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Elizabeth Hunsperger, Momar Ndao, Kay Tomashek, B. Katherine Poole-Smith
  • SERUM BIOMARKERS FOR CHAGAS DISEASE
    Publication number: 20120172356
    Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Chagas disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with Chagas disease or non-infected. The biomarkers can be detected by SELDI mass spectrometry.
    Type: Application
    Filed: October 25, 2011
    Publication date: July 5, 2012
    Applicant: MCGILL UNIVERSITY
    Inventors: Momar NDAO, Brian WARD, Hongshan LI, Vladimir PODUST, Rebecca CAFFREY, Terrance William SPITHILL, Regis PERICHON
  • BIOMARKERS FOR DENGUE
    Publication number: 20120021936
    Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying dengue status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with dengue or not infected with dengue. The biomarkers can be detected by SELDI mass spectrometry.
    Type: Application
    Filed: October 14, 2009
    Publication date: January 26, 2012
    Applicants: Mahidol University, The Royal Institution for the Advancement of Learning/McGill University
    Inventors: Brian Ward, Momar Ndao, Takol Chareonsirisuthikul, Sukathida Ubol
  • Serum biomarkers for Chagas disease
    Patent number: 8043825
    Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Chagas disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with Chagas disease or non-infected. The biomarkers can be detected by SELDI mass spectrometry.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: October 25, 2011
    Assignee: McGill University
    Inventors: Momar Ndao, Brian Ward, Rebecca Caffrey, Terence William Spithill, Hongshan Li, Vladimir Podust, Regis Perichon
  • Biomarkers for Babesia
    Publication number: 20090215086
    Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying babesia status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with babesia or not infected with babesia. The biomarkers can be detected by SELDI mass spectrometry.
    Type: Application
    Filed: December 12, 2006
    Publication date: August 27, 2009
    Inventors: Momar Ndao, Brian Ward, Peter Krause, Mark W. Duncan, Mike Edwards, Terence William Spithill
  • Serum biomarkers for Chagas disease
    Publication number: 20050260691
    Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Chagas disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with Chagas disease or non-infected. The biomarkers can be detected by SELDI mass spectrometry.
    Type: Application
    Filed: December 6, 2004
    Publication date: November 24, 2005
    Applicant: Ciphergen Biosystems, Inc.
    Inventors: Momar Ndao, Brian Ward, Rebecca Caffrey, Terence Spithill, Hongshan Li, Vladimir Podust, Regis Perichon